comparemela.com


Cybin Moves Forward With Clinical Trial On Psilocybin Oral Film
Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced on Tuesday it has received initial clearance to begin a Phase IIa clinical trial on psilocybin for patients suffering from major depressive disorders (MDD).
The head-to-head study will test Cybin’s proprietary sublingual psilocybin formulation against a 25mg psilocybin capsule on 40 patients.
The trial has been approved by a review board at the University of the West Indies in Jamaica, where the research will be undertaken. The company still awaits final confirmation by Jamaica’s Ministry of Health to begin testing the product on human subjects.

Related Keywords

Jamaica ,Canada ,University Of The West Indies ,Saint Andrew ,Jamaican ,Doug Drysdale ,Jamaica Ministry Of Health ,Cybin Inc ,Intelgenx Corp ,International Conference On Harmonization ,West Indies ,International Conference ,Harmonization Good Clinical Practice ,ஜமைக்கா ,கனடா ,பல்கலைக்கழகம் ஆஃப் தி மேற்கு இண்டீஸ் ,துறவி ஆண்ட்ரூ ,டக் ட்ரைஸ்டேல் ,ஜமைக்கா அமைச்சகம் ஆஃப் ஆரோக்கியம் ,மேற்கு இண்டீஸ் ,சர்வதேச மாநாடு ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.